Imidazolium salts as small-molecule urinary bladder exfoliants in a murine model

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5494-5502

  Wagers, Patrick O ^a   Tiemann, Kristin M ^b   Shelton, Kerri L ^a   Kofron, William G ^a   Panzner, Matthew J ^a   Wooley, Karen L ^c   Youngs, Wiley J ^a   Hunstad, David A ^b  

^a UNIVERSITY OF AKRON   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Electrical and Computer Engineering   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIDAZOLE DERIVATIVE; IMIDAZOLIUM SALT; INORGANIC SALT; UNCLASSIFIED DRUG; UROPLAKIN; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER EPITHELIUM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG PURIFICATION; DRUG STABILITY; DRUG SYNTHESIS; EXFOLIATIVE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BLADDER; C57BL MOUSE; CELL LINE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; ESCHERICHIA COLI; UROTHELIUM;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; CELL SURVIVAL; ESCHERICHIA COLI; FEMALE; HUMANS; IMIDAZOLES; MICE; MICE, INBRED C57BL; URINARY BLADDER; UROTHELIUM;

EID: 84940904027     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00881-15     Document Type: Article

References (35)

1. Sun TT, Zhao H, Provet J, Aebi U, Wu XR 1996. Formation of asymmetric unit membrane during urothelial differentiation. Mol Biol Rep 23:3-11. http://dx.doi.org/10.1007/BF00357068.
2. Foxman B. 2010. The epidemiology of urinary tract infection. Nat Rev Urol 7:653-660. http://dx.doi.org/10.1038/nrurol.2010.190.
3. Min G, Stolz M, Zhou G, Liang F, Sebbel P, Stoffler D, Glockshuber R, Sun TT, Aebi U, Kong XP 2002. Localization of uroplakin Ia, the urothelial receptor for bacterial adhesin FimH, on the six inner domains of the 16 nm urothelial plaque particle. J Mol Biol 317:697-706. http://dx.doi.org/10.1006/jmbi.2002.5442.
4. Wu XR, Sun TT, Medina JJ 1996. In vitro binding of type 1-fimbriated Escherichia coli to uroplakins 1a and 1b: relation to urinary tract infections. Proc Natl Acad Sci U S A 93:9630-9635. http://dx.doi.org/10.1073/pnas.93.18.9630.
5. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ 2003. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301:105-107. http://dx.doi.org/10.1126/science.1084550.
6. Ulett GC, Totsika M, Schaale K, Carey AJ, Sweet MJ, Schembri MA 2013. Uropathogenic Escherichia coli virulence and innate immune responses during urinary tract infection. Curr Opin Microbiol 16:100-107. http://dx.doi.org/10.1016/j.mib.2013.01.005.
7. Mulvey MA, Lopez-Boado YS, Wilson CL, Roth R, Parks WC, Heuser J, Hultgren SJ 1998. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282:1494-1497. http://dx.doi.org/10.1126/science.282.5393.1494.
8. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ 2007. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 4:e329. http://dx.doi.org/10.1371/journal.pmed.0040329.
9. Hunstad DA, Justice SS 2010. Intracellular lifestyles and immune evasion strategies of uropathogenic Escherichia coli. Annu Rev Microbiol 64: 203-221. http://dx.doi.org/10.1146/annurev.micro.112408.134258.
10. Mysorekar IU, Hultgren SJ 2006. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci U S A 103:14170-14175. http://dx.doi.org/10.1073/pnas.0602136103.
11. Mysorekar IU, Isaacson-Schmid M, Walker JN, Mills JC, Hultgren SJ 2009. Bone morphogenetic protein4 signaling regulates epithelial renewal in the urinary tract in response to uropathogenic infection. Cell Host Microbe 5:463-475. http://dx.doi.org/10.1016/j.chom.2009.04.005.
12. Blango MG, Mulvey MA 2010. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother 54:1855-1863. http://dx.doi.org/10.1128/AAC.00014-10.
13. Mulvey MA, Schilling JD, Hultgren SJ 2001. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun 69:4572-4579. http://dx.doi.org/10.1128/IAI.69.7.4572-4579.2001.
14. Schilling JD, Lorenz RG, Hultgren SJ 2002. Effect of trimethoprim-sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic Escherichia coli. Infect Immun 70:7042-7049. http://dx.doi.org/10.1128/IAI.70.12.7042-7049.2002.
15. Blango MG, Ott EM, Erman A, Veranic P, Mulvey MA 2014. Forced resurgence and targeting of intracellular uropathogenic Escherichia coli reservoirs. PLoS One 9:e93327. http://dx.doi.org/10.1371/journal.pone.0093327.
16. Russell AD, Hugo WB 1994. Antimicrobial activity and action of silver. Prog Med Chem 31:351-370. http://dx.doi.org/10.1016/S0079-6468(08)70024-9.
17. Holland CL, Singh AK, McMaster PR, Fang W. 1984. Adverse reactions to protamine sulfate following cardiac surgery. Clin Cardiol 7:157-162. http://dx.doi.org/10.1002/clc.4960070305.
18. Lakin JD, Blocker TJ, Strong DM, Yocum MW 1978. Anaphylaxis to protamine sulfate mediated by a complement-dependent IgG antibody. J Allergy Clin Immunol 61:102-107. http://dx.doi.org/10.1016/0091-6749(78)90232-4.
19. Nybo M, Madsen JS 2008. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic Clin Pharmacol Toxicol 103:192-196. http://dx.doi.org/10.1111/j.1742-7843.2008.00274.x.
20. Sanchez MB, Paolillo M, Chacon RS, Camejo M. 1982. Protamine as a cause of generalised allergic reactions to NPH insulin. Lancet i:1243.
21. Lavelle J, Meyers S, Ramage R, Doty D, Bastacky S, Apoddaca G, Zeidel M. 2001. Protamine sulfate-induced cystitis: a model of selective cytodestruction of the urothelium. Urology 57(6 Suppl 1):113. http://dx.doi.org/10.1016/S0090-4295(01)01047-0.
22. Niku SD, Stein PC, Scherz HC, Parsons CL 1994. A new method for cytodestruction of bladder epithelium using protamine sulfate and urea. J Urol 152:1025-1028.
23. Tzan CJ, Berg J, Lewis SA 1993. Effect of protamine sulfate on the permeability properties of the mammalian urinary bladder. J Membr Biol 133:227-242.
24. Chuang YC, Chancellor MB, Seki S, Yoshimura N, Tyagi P, Huang L, Lavelle JP, De Groat WC, Fraser MO 2003. Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity. Urology 61:664-670. http://dx.doi.org/10.1016/S0090-4295(02)02280-X.
25. Sinanoglu O, Dogan Ekici I, Ekici S. 2014. Comparison of intravesical application of chondroitin sulphate and colchicine in rat protamine/lipopolysaccharide induced cystitis model. Urol J 11:1296-1300.
26. Soler R, Bruschini H, Freire MP, Alves MT, Srougi M, Ortiz V. 2008. Urine is necessary to provoke bladder inflammation in protamine sulfate induced urothelial injury. J Urol 180:1527-1531. http://dx.doi.org/10.1016/j.juro.2008.06.006.
27. Bollini M, Casal JJ, Bruno AM 2008. Design, synthesis, and antitumor activity of new bis-aminomethylnaphthalenes. Bioorg Med Chem 16: 8003-8010. http://dx.doi.org/10.1016/j.bmc.2008.07.069.
28. Sheldrick GM. 2008. A short history of SHELX. Acta Crystallogr A 64: 112-122. http://dx.doi.org/10.1107/S0108767307043930.
29. Stemler KM, Crock LW, Lai HH, Mills JC, Gereau RW, IV, Mysorekar IU. 2013. Protamine sulfate induced bladder injury protects from distention induced bladder pain. J Urol 189:343-351. http://dx.doi.org/10.1016/j.juro.2012.08.189.
30. Hung CS, Dodson KW, Hultgren SJ 2009. A murine model of urinary tract infection. Nat Protoc 4:1230-1243. http://dx.doi.org/10.1038/nprot.2009.116.
31. Danka ES, Hunstad DA 2015. Cathelicidin augments epithelial receptivity and pathogenesis in experimental Escherichia coli cystitis. J Infect Dis 211:1164-1173. http://dx.doi.org/10.1093/infdis/jiu577.
32. Wright BD, Deblock MC, Wagers PO, Duah E, Robishaw NK, Shelton KL, Southerland MR, DeBord MA, Kersten KM, McDonald LM, Stiel JA, Panzner MJ, Tessier CA, Paruchuri S, Youngs WJ. 13 February 2015. Anti-tumor activity of lipophilic imidazolium salts on select NSCLC cell lines. Med Chem Res http://dx.doi.org/10.1007/s00044-015-1330-z.
33. Clemens JQ, Mullins C, Kusek JW, Kirkali Z, Mayer EA, Rodriguez LV, Klumpp DJ, Schaeffer AJ, Kreder KJ, Buchwald D, Andriole GL, Lucia MS, Landis JR, Clauw DJ. 2014. The MAPP research network: a novel study of urologic chronic pelvic pain syndromes. BMC Urol 14:57. http://dx.doi.org/10.1186/1471-2490-14-57.
34. Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, N'Dow J, Nabi G, Cook J, Vale L. 2010. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 14(4):1-331. http://dx.doi.org/10.3310/hta14040.
35. Huber S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G, Mayer T, Gawrych K, Bonberg N, Pelster M, Johnen G, Bontrup H, Wellhausser H, Bierfreund HG, Wiens C, Bayer C, Eberle F, Scheuermann B, Kluckert M, Feil G, Bruning T, Stenzl A, UroScreen Study Group. 2012. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the Uro-Screen study. BJU Int 110:699-708. http://dx.doi.org/10.1111/j.1464-410X.2011.10883.x.